How can a monoclonal antibody treatment contribute to eradicate chronic HBV infection?
Current antivirals cannot cure HBV on their own. ADRI-2F3 is a fully human mAb that completely neutralize HBV, removing excess virus and restoring HBV-specific immune responses. This will allow antiviral drugs to be more efficient in HBV eradication. ADRI-2F3 can also be used to prevent mother-to-child HBV transmission, before vaccination, and to prevent HBV reinfection after liver grafts.
Mario U Mondelli is a Professor of Infectious Diseases at Pavia University and Director of the Division of Clinical Immunology and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. He is well known in the community of liver specialists, having served as Secretary General in the European Association for the Study of the Liver (EASL) and as Editor of the Journal of Hepatology and Liver International. He received the prestigious EASL Recognition Award for scientific merits in 2018. His major research interests have focused on immune responses in viral hepatitis B and C and liver cancer throughout his professional life. He and his group have specific expertise on human monoclonal antibody development. A recently patented antibody specific for hepatitis B virus has shown potent virus neutralizing activity in preclinical studies.